Abstract:Nearly every extracellular ligand that has been found to play a role in regulating bone biology acts, at least in part, through MAPK pathways. Nevertheless, much remains to be learned about the contribution of MAPKs to osteoblast biology in vivo. Here we report that the p38 MAPK pathway is required for normal skeletogenesis in mice, as mice with deletion of any of the MAPK pathway member-encoding genes MAPK kinase 3 (Mkk3), Mkk6, p38a, or p38b displayed profoundly reduced bone mass secondary to defective osteoblast differentiation. Among the MAPK kinase kinase (MAP3K) family, we identified TGF-beta-activated kinase 1 (TAK1; also known as MAP3K7) as the critical activator upstream of p38 in osteoblasts. Osteoblast-specific deletion of Tak1 resulted in clavicular hypoplasia and delayed fontanelle fusion, a phenotype similar to the cleidocranial dysplasia observed in humans haploinsufficient for the transcription factor runt-related transcription factor 2 (Runx2). Mechanistic analysis revealed that the TAK1-MKK3/6-p38 MAPK axis phosphorylated Runx2, promoting its association with the coactivator CREB-binding protein (CBP), which was required to regulate osteoblast genetic programs. These findings reveal an in vivo function for p38beta and establish that MAPK signaling is essential for bone formation in vivo. These results also suggest that selective p38beta agonists may represent attractive therapeutic agents to prevent bone loss associated with osteoporosis and aging.

Supplementary Figure 1 from P38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss Via Suppressing Osteoclastogenesis in Mice

P38α MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions

p38α MAPK regulates proliferation and differentiation of osteoclast progenitors and bone remodeling in an aging-dependent manner

Figure S3 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

The P38 MAPK Pathway is Essential for Skeletogenesis and Bone Homeostasis in Mice.

Figure S2 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Figure S4 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Figure S5 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Figure S3 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figures 1-7 from <i>Pten</i> Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

Activation of p38 mitogen-activated protein kinase is required for osteoblast differentiation.

Figure S7 from P38γ MAPK is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis

Supplementary Figure 9 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

p38 MAPK Signaling in Osteoblast Differentiation

p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix.

Supplementary Data from mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK

Supplementary Figure 6 from Reciprocal Interactions Between Tumor-Associated Macrophages and CD44-Positive Cancer Cells Via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer

Effects of P38mapk on Proliferating Cycle and Apoptosis of Murine Osteoblasts